RT @SantoshVardhana: Thrilled to have contributed to one of @BCD_AACR top 5 most cited articles in what was a wonderful submission process…

RT @SantoshVardhana: Thrilled to have contributed to one of @BCD_AACR top 5 most cited articles in what was a wonderful submission process…

Thrilled to have contributed to one of @BCD_AACR top 5 most cited articles in what was a wonderful submission process - thanks again to @_TanyaBondar_ and kudos to @DavidJChungMD and @DavidKnorrMDPhD!

Disease- and Therapy-Specific Impact on Humoral Immune Responses to #COVID19 Vaccination in #HematologicMalignancies, by @DavidJChungMD et al. https://t.co/4Wq3I2e0gT @MSKCancerCenter @WeillCornell https://t.co/Ebxt8YQw1X

RT @BCD_AACR: Referenced in the #AACRCOVIDReport: Disease and therapy-specific impact on humoral immune responses to #COVID19 vaccination i…

Referenced in the #AACRCOVIDReport: Disease and therapy-specific impact on humoral immune responses to #COVID19 vaccination in hematologic malignancies by Chung, Knorr, et al. https://t.co/31xcuuIaDM https://t.co/IkFfAEavZ4

Referenced in the #AACRCOVIDReport: Disease and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies. https://t.co/9YAddVCoKX

#ICYMI: Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies by David A. Knorr, David J. Chung and colleagues. https://t.co/cblACYsh8J https://t.co/PkaA3DdNW8

Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies https://t.co/NWJCWp8SsI new article

#Myeloma Paper of the Day: Study of disease- and therapy-specific impact on humoral responses to #COVID-19 vaccination in hematologic malignancy patients finds single agent IMiDs didn't blunt response but other anti-myeloma therapies did: https://t.co/dyuw

Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies #lymphoma #lymsm https://t.co/iVH3NKqJLu

New article: Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies https://t.co/Efd7cXUWGE #coronavirus #COVID19 #2019ncov https://t.co/wkKTLi9zC1

New article: Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies https://t.co/cymiLc1gdE #MMSM #MultipleMyeloma #hematology https://t.co/jotMqav916

@COVID19nCCC @mtmdphd @rubinstein_md

RT @DrRaulCordoba: #Hematology Disease- and Therapy-Specific Impact on Humoral Immune Responses to #COVID19Vaccination in Hematologic Malig…

#Hematology Disease- and Therapy-Specific Impact on Humoral Immune Responses to #COVID19Vaccination in Hematologic Malignancies #lymsm #leusm #mmsm #COVID19 #vaccines https://t.co/iJ55Gt8xgT

ICYMI: In cohort of 551, protection level by neutralizing Ab is lower than by total titers. Venetoclax, BTKi, PI3Ki & B-cell antigen-targeting therapies hinder Ab response, while IMID don’t. Response higher in females than males and to Moderna vs Pfize

RT @MSKHemOncTrials: Disease and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies @B…

Disease and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies @BCD_AACR @sloan_kettering @GunjanLShah @SantoshVardhana @DavidJChungMD #COVID19 https://t.co/nhl7IPUfy7

RT @_TanyaBondar_: Excellent talk by @VardhanaLab @sloan_kettering at #AACRtii21 yesterday on #COVID19 vaccine responses in cancer patients…

RT @_TanyaBondar_: Excellent talk by @VardhanaLab @sloan_kettering at #AACRtii21 yesterday on #COVID19 vaccine responses in cancer patients…

Excellent talk by @VardhanaLab @sloan_kettering at #AACRtii21 yesterday on #COVID19 vaccine responses in cancer patients, including data published this month in this @BCD_AACR paper: https://t.co/6s55FcPPWP

RT @ElizSMcKenna: ICYMI in our sister journal @BCD_AACR: Disease and therapy-specific impact on humoral immune responses to #COVID19 #vacci…

RT @ElizSMcKenna: ICYMI in our sister journal @BCD_AACR: Disease and therapy-specific impact on humoral immune responses to #COVID19 #vacci…

RT @_TanyaBondar_: And thanks to @DavidKnorrMDPhD @tamari_roni @sloan_kettering for contributing data for the analysis ahead of publication…

RT @ElizSMcKenna: ICYMI in our sister journal @BCD_AACR: Disease and therapy-specific impact on humoral immune responses to #COVID19 #vacci…

And thanks to @DavidKnorrMDPhD @tamari_roni @sloan_kettering for contributing data for the analysis ahead of publication. These findings had a major impact on overall conclusions and policy recommendations. https://t.co/R8C88hiTLA https://t.co/K16mKQNoyP

ICYMI in our sister journal @BCD_AACR: Disease and therapy-specific impact on humoral immune responses to #COVID19 #vaccination in #hematologicmalignancies @SantoshVardhana @DavidKnorrMDPhD @sloan_kettering @WeillCornell @RockefellerUniv https://t.co/GtXML

RT @BCD_AACR: @sloan_kettering A cohort of 551 levels of protection by neutralizing Ab is lower than by total titers. Venetoclax, BTKi, PI3…

RT @BCD_AACR: @sloan_kettering A cohort of 551 levels of protection by neutralizing Ab is lower than by total titers. Venetoclax, BTKi, PI3…

@sloan_kettering A cohort of 551 levels of protection by neutralizing Ab is lower than by total titers. Venetoclax, BTKi, PI3Ki & B-cell antigen-targeting therapies hinder Ab response, while IMID doesn’t. The response is higher in females than males &a